Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Gains After Positive RV01 Preclinical Findings

June 02, 2025 04:56 PM AEST | By Sonal Goyal

Google News:

Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Gains After Positive RV01 Preclinical Findings — Image source: Company update

Recent News

Lithium Universe Eyes Greener Horizons with Solar Recycling Breakthrou...

ASX Momentum Builds as Lithium and Graphite Stocks Spark All Ordinarie...

Tin Potential on the Rise: Why Metals X (ASX:MLX) Could Be a Standout...

Shore Surgery Specialist Day Hospital Selects Provation® to Streamline...

Highlights

RV01, a Lu177-labelled B7-H3-targeted monoclonal antibody, showed favourable biodistribution and sustained high tumour uptake in preclinical studies.

RV01 incorporates Fc region modifications to shorten its half-life, potentially reducing off-target radiation exposure and associated toxicities.

Radiopharm plans to submit an Investigational New Drug (IND) application by mid-2025, with a first-in-human basket study expected to begin by year-end.

Radiopharm Theranostics’ (ASX:RAD, Nasdaq:RADX) share price jumped over 16% to AUD 0.028 on 2 June 2025, following the release of latest preclinical data for its B7-H3-targeted radiopharmaceutical therapy, RV01.

Preclinical studies using the Lu177-B7H3-monoclonal antibody (RV01) showed favourable biodistribution and sustained high tumour uptake. The engineered modifications to the monoclonal antibody (mAb) resulted in a shorter lifespan compared to traditional mAbs. These changes, along with other Fc modifications, helps minimise off-target exposure to the isotope and reduce toxicities commonly associated with conventional mAb therapies.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.